Navigation Links
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Date:6/26/2009

DEERFIELD, Ill., June 26, and OSAKA, Japan, June 27, 2009 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary received on June 26 (U.S. time) a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA and Takeda have been in discussions about conducting an additional cardiovascular study for alogliptin.

As previously announced on March 6, 2009, the FDA informed Takeda that, although the alogliptin NDA was filed prior to the release of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that Guidance. The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA Guidance.

"Takeda will continue to promote key initiatives in order to realize sustained growth from a medium- to long-term perspective," said Takeda President & CEO, Yasuchika Hasegawa.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its co
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 ... Assay Market by Product (Consumables, Instruments, Services), by Test ... (ELISA, Chromatography, Flow Cytometry), by End Users - Global ... Assays Market is expected to reach $736.85 Million by ... CAGR of 10.25%. Browse 71 market ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
(Date:5/22/2015)... PA (PRWEB) May 22, 2015 According to ... a hub for drug related death, totaling almost 2,500 confirmed ... as reported by state officials, totals 2,489 deaths stemming from ... work out, Pennsylvania loses seven people every day to fatal ... has been singled out as one of the most rife ...
(Date:5/22/2015)... VA (PRWEB) May 22, 2015 sweetFrog Enterprises, ... location in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog ... yogurt chain was listed as #22 on the Inc. 500 ... “I have lived and worked in East Texas for 20 ... Brad Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog ...
(Date:5/22/2015)... Ticket Down is a reputable source for authentic ... Conference Finals Tickets . All seating for the 2015 ... ticket listing. , For the first time in some ... the Eastern Conference. One of the original franchises in the ... downs over the years, but the excitement level for this ...
(Date:5/22/2015)... Co founders Greenlee and James Chapko, DDS have launched a ... deliver fully integrated dental implant services to their patients. ... , The Center, whose name is ImplantWide, LLC ... dental implants. These 6 roadblocks can discourage any dentist ... of dental implants into his or her practice. ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 In efforts ... patrons, the section containing particular muscles stretches has been ... nearly 50% of stretches now complete, Chunk Fitness envisions ... planned to be filmed and released at a later ... be found here: http://www.chunkfitness.com/stretches . , About the ...
Breaking Medicine News(10 mins):Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2
... Skeletal findings suggest men fighting over women took place even ... Men fighting over women? Nothing new there, based on the ... , Durham University-led researchers say that genetic evidence from 34 ... were the result of a tribal war over the need ...
... Md., June 13 The Blinded,American Veterans Foundation (BAVF), ... honor Maryland State Delegate Sheila Hixson., "We,re honored ... residents of Maryland,s District 20 and to the entire ... Spring, MD. "Her,tireless efforts as a legislator and community ...
... Cause of Work Disability in Europe, PARIS, ... treating patients with early, active rheumatoid arthritis (RA),with ... an,indirect cost savings of euro 4,845 (or approximately ... study) per patient per year compared to,MTX treatment ...
... of Mesothelioma Victim Will Address Effort to Find ... Lexi,Miletto, whose grandfather, Joseph Miletto died in 2005 ... the Gala Dinner on Friday,evening, June 27th, part ... Malignant Mesothelioma, which runs Thursday,June 26th through Saturday, ...
... LAUDERDALE, Fla., June 12 Synovics,Pharmaceuticals, Inc., (OTC ... that on June 6, 2008, it formalized,a strategic ... of a joint venture ("JV"). The JV between ... vehicle for Synovics to have access,to assets of ...
... reduction in time awake and a drop in anxiety levels ... moderate aerobic exercise can help reduce anxiety and improve the ... study. Heavy aerobic or moderate strength exercises don,t have the ... Sao Paulo divided 28 women and eight men with primary ...
Cached Medicine News:Health News:Pursuit of Females Dates Way, Way Back 2Health News:Blinded Vets Foundation to Honor Maryland State Delegate Sheila Hixson 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 4Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 5Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 6Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 7Health News:Asbestos Tragedy and Hope 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 4Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 5Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 6
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... Standard/Conventional Blade. Stainless steel. Lamp supplied ... tradition of high quality standard incandescent ... blades have been continually refined through ... over to minimize maintenance requirements. They ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
Medicine Products: